Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vandetanib in EGFR TKI-pretreated NSCLC (ZEPHYR)
NCT00404924Phase 3Completed
- Sponsor
- Sanofi
- Start
- Nov 2006
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 22
01
Overview
A Phase 3 trial of vandetanib in non-small cell lung cancer (NSCLC), sponsored by Sanofi. Started Nov 2006; status: completed.
02
Drugs
vandetanib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00404924.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00404924.